Evidence-informed educational review. Updated 10 November 2026. Follow current local product labeling and individualized clinical guidance.
Histamine released in the stomach stimulates H2 receptors on parietal cells and increases acid secretion. Famotidine, cimetidine and other H2-receptor antagonists reversibly block that signal. They reduce basal acid secretion, particularly overnight, and can help with intermittent heartburn. Continuous treatment can produce tolerance, so a patient who initially slept better may experience recurrent nighttime symptoms despite taking the same dose. [1, 2]
Chemical classes and receptor signalling
H2RAs are structurally distinct, not a single ‘imidazoline class’: cimetidine has an imidazole ring, famotidine contains a thiazole-related moiety, and nizatidine is a different heterocyclic derivative. Competitive/inverse-agonist effects at Gs-coupled H2 receptors reduce cAMP-dependent stimulation of gastric H+/K+-ATPase. The effect is particularly useful for nocturnal acid secretion but is weaker than PPI inhibition of the final secretory step [3].
Selecting treatment
For occasional reflux without alarm symptoms, intermittent H2 blockade can be useful. For documented erosive esophagitis, proton pump inhibitors (PPIs) are more effective for healing and maintaining healing. In someone already taking a PPI who still wakes with reflux, check adherence and meal timing before adding another drug. An as-needed bedtime H2 antagonist may help selected patients with persistent nocturnal symptoms. [2]
Famotidine also has labelled indications for gastric and duodenal ulcers. Improving epigastric discomfort does not establish that an ulcer has healed. When an ulcer is identified, investigate causes such as Helicobacter pylori infection and NSAID exposure, because acid suppression alone can leave the cause in place. [4, 5]
Renal clearance and interactions
Famotidine is eliminated substantially by the kidneys. The US tablet label calls for dose adjustment below a creatinine clearance of 60 mL/min. The recommended maximum dose or interval depends on the indication and degree of impairment. This matters in an older patient who develops confusion after starting famotidine: reassess renal function, dose and other causes of delirium. Central nervous system reactions and prolonged QT intervals have been reported with moderate or severe renal impairment. [4]
Cimetidine inhibits several hepatic CYP enzymes and can raise concentrations of interacting drugs, including warfarin and phenytoin. Famotidine has fewer CYP-mediated interactions. Both drugs can change absorption of medicines that require an acidic stomach, so switching between H2 antagonists does not remove every interaction. [1, 4]
Ranitidine status in the United States
Earlier ranitidine products were withdrawn over concerns about the nitrosamine NDMA. On 24 November 2025 the FDA approved reformulated tablets. The revised instructions specify keeping tablets in their original moisture-protective bottle and discarding unused tablets 90 days after opening or at expiry, whichever occurs first. This approval applies to the reformulated US product. [6]
References
- H2 blockers. In: StatPearls. Treasure Island (FL): StatPearls Publishing. [cited 2026 Nov 10]. View source.
- Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline: guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117:27–56. [cited 2026 Nov 10]. View source.
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- National Library of Medicine. Famotidine tablets. DailyMed prescribing information. [cited 2026 Nov 10]. View source.
- National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for peptic ulcers (stomach or duodenal ulcers). [cited 2026 Nov 10]. View source.
- US Food and Drug Administration. FDA approves reformulated ranitidine following comprehensive safety review. 2025 Nov 24. [cited 2026 Nov 10]. View source.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.